NovoCure (NVCR) stock price, revenue, and financials

NovoCure market cap is $12.5 b, and annual revenue was $494.37 m in FY 2020

$12.5 B

NVCR Mkt cap, 22-Oct-2021

$134.7 M

NovoCure Revenue Q1, 2021
NovoCure Gross profit (Q1, 2021)108.3 M
NovoCure Gross profit margin (Q1, 2021), %80.4%
NovoCure Net income (Q1, 2021)-4.1 M
NovoCure EBIT (Q1, 2021)-88 K
NovoCure Cash, 31-Mar-2021314.5 M
NovoCure EV12.7 B
Get notified regarding key financial metrics and revenue changes at NovoCureLearn more
Banner background

NovoCure Revenue

NovoCure revenue was $494.37 m in FY, 2020 which is a 40.7% year over year increase from the previous period.

Embed Graph

NovoCure Revenue Breakdown

Embed Graph

NovoCure revenue breakdown by geographic segment: 5.9% from Japan, 18.9% from Germany, 68.9% from United States and 6.3% from Other

NovoCure Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

248.1m351.3m494.4m

Revenue growth, %

42%41%

Cost of goods sold

80.0m88.6m106.5m

Gross profit

168.0m262.7m387.9m

Gross profit Margin, %

68%75%78%

Sales and marketing expense

77.7m96.7m118.0m

R&D expense

50.6m79.0m132.0m

General and administrative expense

73.5m87.9m107.4m

Operating expense total

201.7m263.6m357.5m

EBIT

(33.7m)(914.0k)30.4m

EBIT margin, %

(14%)0%6%

Interest expense

12.3m7.9m12.3m

Pre tax profit

(45.9m)(8.8m)18.1m

Income tax expense

17.6m(1.6m)(1.7m)

Net Income

(63.6m)(7.2m)19.8m

EPS

(0.7)(0.1)0.2

NovoCure Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

140.6m177.3m234.7m

Accounts Receivable

36.5m58.9m96.7m

Inventories

22.6m23.7m27.4m

Current Assets

321.4m439.9m999.4m

PP&E

8.4m9.3m11.4m

Total Assets

339.8m479.4m1.1b

Accounts Payable

26.7m36.9m53.6m

Current Liabilities

64.6m86.3m113.6m

Long-term debt

149.3m163.6m444.2m

Non-Current Liabilities

163.0m175.3m461.8m

Total Debt

149.3m163.6m444.2m

Total Liabilities

227.5m261.7m575.5m

Additional Paid-in Capital

757.3m871.4m1.1b

Retained Earnings

(643.7m)(650.9m)(631.1m)

Total Equity

112.3m217.8m476.5m

Debt to Equity Ratio

1.3 x0.8 x0.9 x

Debt to Assets Ratio

0.4 x0.3 x0.4 x

Financial Leverage

3 x2.2 x2.2 x

NovoCure Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(63.6m)(7.2m)19.8m

Depreciation and Amortization

9.0m8.5m9.2m

Accounts Receivable

(4.2m)(36.5m)(30.4m)

Inventories

(529.0k)(1.2m)(2.9m)

Accounts Payable

9.5m16.9m25.5m

Cash From Operating Activities

(1.9m)26.6m99.1m

Purchases of PP&E

(2.9m)(10.5m)(15.0m)

Cash From Investing Activities

(5.5m)(51.7m)(472.8m)

Long-term Borrowings

(100.1m)(31.0k)(150.0m)

Cash From Financing Activities

69.4m61.7m440.2m

Net Change in Cash

62.0m36.7m66.8m

Interest Paid

13.3m13.7m8.7m

Income Taxes Paid

20.4m11.2m(3.3m)

NovoCure Ratios

USDQ1, 2018

Debt/Equity

1.4 x

Debt/Assets

0.5 x

Financial Leverage

2.9 x

NovoCure Operating Metrics

FY, 2018FY, 2019FY, 2020May, 2021

Patents and Patent Applications

140180185

Phase II Trials Products

2232

Phase III Trials Products

3454

Trials Products Approved

13

NovoCure Employee Rating

4.163 votes
Culture & Values
3.6
Work/Life Balance
3.4
Senior Management
3.3
Salary & Benefits
3.2
Career Opportunities
3.3
Source